High dose biotin as treatment for progressive multiple sclerosis
Authors:
- 1 November 2017
- journal article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 18, 141-143
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Efficacy of Siponimod in Secondary Progressive Multiple Sclerosis: Results of the Phase 3 Study (CT.002)Neurology, 2017
- Mitochondria in Multiple Sclerosis: Molecular Mechanisms of Pathogenesis2017
- Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosisNeuropharmacology, 2016
- MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled studyMultiple Sclerosis Journal, 2016
- Factitious Graves' Disease Due to Biotin Immunoassay Interference—A Case and Review of the LiteratureThe Journal of Clinical Endocrinology & Metabolism, 2016
- Misdiagnosis of Graves' Disease with Apparent Severe Hyperthyroidism in a Patient Taking Biotin MegadosesThyroid®, 2016
- Dalfampridine may activate latent trigeminal neuralgia in patients with multiple sclerosisNeurology, 2014
- Defining the clinical course of multiple sclerosisNeurology, 2014
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011
- Cerebrospinal fluid levels of biotin in various neurological disordersActa Neurologica Scandinavica, 1999